Adicet Bio to Present ADI-270 Preclinical Data at 2024 EHA Congress

Adicet Bio, a clinical stage biotechnology company, announces the acceptance of a poster presentation featuring preclinical data on ADI-270, an armored allogeneic anti-CD70 CAR γδ T cell therapy, at the 2024 European Hematology Association (EHA) Hybrid Congress in Madrid, Spain. The presentation highlights the potential of ADI-270 as a promising therapeutic approach for various cancer indications, showcasing Adicet Bio's commitment to advancing innovative allogeneic gamma delta T cell therapies. This description focuses on the primary topic (Adicet Bio's poster presentation on ADI-270), the main entity (Adicet Bio), the context (2024 EHA Hybrid Congress in Madrid, Spain), and the significant action (presentation of preclinical data on ADI-270). The description also provides objective and relevant details that will help an AI generate an accurate visual representation of the article's content, such as the setting of the congress and the type of therapy being presented.

author-image
Bijay Laxmi
New Update
Adicet Bio to Present ADI-270 Preclinical Data at 2024 EHA Congress

Adicet Bio to Present ADI-270 Preclinical Data at 2024 EHA Congress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company, has announced the acceptance of a poster presentation featuring preclinical data on ADI-270, an armored allogeneic anti-CD70 CAR γδ T cell therapy, at the upcoming European Hematology Association (EHA) Hybrid Congress in Madrid, Spain from June 13-16, 2024.

Why this matters: The development of innovative cancer therapies like ADI-270 has the potential to improve treatment outcomes and quality of life for patients with solid and hematological cancers. Furthermore, advancements in allogeneic gamma delta T cell therapies could lead to more accessible and cost-effective treatment options for a broader range of patients.

The poster presentation, titled "ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications," will be presented by Yvan Chanthery, Ph.D. on June 14, 2024 at 18:00 CEST. ADI-270 is designed to target multiple solid and hematological cancer indications.

Adicet Bio is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company focuses on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

The European Hematology Association Hybrid Congress is a premier event in the field of hematology, bringing together experts from around the world to share the latest research and advancements. Adicet Bio's presentation at this prestigious conference highlights the potential of ADI-270 as a promising therapeutic approach for various cancer indications.

With the acceptance of this poster presentation, Adicet Bio continues to showcase its commitment to advancing innovative allogeneic gamma delta T cell therapies. The preclinical data on ADI-270 presented at the EHA Hybrid Congress will provide valuable insights into its potential as a novel treatment option for patients with solid and hematological cancers.

Key Takeaways

  • Adicet Bio's ADI-270 poster presentation accepted at 2024 European Hematology Association Hybrid Congress.
  • ADI-270 is an armored allogeneic anti-CD70 CAR γδ T cell therapy for solid and hematological cancers.
  • Presentation highlights potential of ADI-270 as a promising therapeutic approach for various cancer indications.
  • Adicet Bio advances "off-the-shelf" gamma delta T cells for autoimmune diseases and cancer.
  • Preclinical data on ADI-270 to be presented on June 14, 2024, at 18:00 CEST.